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Abstract
Background: Ivermectin is used extensively globally for treatment of helminthic and ectoparasitic infections in
animals and humans. The effect of excreted ivermectin on non-target organisms in aquatic and terrestrial
environments has been increasingly reported. Due to its low water solubility and adsorption to sediments, the
ivermectin exposure-risk to aquatic organisms dwelling in different strata of water bodies varies. This study assessed
the survival of larvae of Anopheles gambiae Giles and Culex quinquefasciatus Say, when exposed to low
concentrations of ivermectin under laboratory conditions.
Methods: A total of 1800 laboratory reared mosquito larvae of each species were used in the bioassays. Twelve
replicates were performed, each testing 6 concentrations of ivermectin (0.0, 0.001, 0.01, 0.1, 1.0 and 10.0 parts per
million (ppm)) against third instar larvae of An. gambiae and Cx. quinquefasciatus. Larval mortality was recorded at
24 and 48 h post addition of ivermectin.
Results: Survival declined markedly with increase in ivermectin concentration in both species. While mean survival
of An. gambiae at 24 h of exposure was 99.6 %, 99.2 % and 61.6 % in 0.001, 0.01 and 0.1 ppm of ivermectin,
respectively, the mean survival of Cx. quinquefasciatus at the same dosage and time was 89.2 %, 47.2 % and 0.0 %.
A similar pattern, but with higher mortality, was observed after 48 h of exposure. Comparison between the species
revealed that Cx. quinquefasciatus larvae were significantly more affected by ivermectin than those of An. gambiae,
both at 24 and 48 h.
Conclusions: Low concentrations of ivermectin in the aquatic environment reduced the survival of larvae of An.
gambiae and Cx. quinquefasciatus, with the effect being more marked in the latter species. It is suggested that this
difference may be due to the different water strata occupied by the two species, with ivermectin adsorbed in food
that sediment being more readily available to the bottom feeding Cx. quinquefasciatus than the surface feeding An.
gambiae larvae.
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Background
Ivermectin is an important drug for treatment of many
helminthic and ectoparasitic infections in animals and
humans globally [1]. It has been extensively used in the
veterinary field, and its use in humans has recently been
scaled up in large programmes to control lymphatic fil-
ariasis and onchocerciasis in endemic areas particularly
in sub-Saharan Africa [2, 3]. Due to its effectiveness in
treating these infections, many of which are particularly
common in the tropics, it has been referred to as a ‘won-
der drug’ [4]. However, in addition to the anti-parasitic
potentials, ivermectin has a broad spectrum of activity
against a wide range of other invertebrates, and its effect
in the environment on non-target aquatic and terrestrial
organisms has been increasingly documented [5].
In relation to its broad spectrum of activity, the ongoing
Global Programme to Eliminate Lymphatic Filariasis has
reported promising beyond-programme benefits of iver-
mectin mass drug administration (MDA), including
simultaneous curative effects on intestinal and skin* Correspondence: yderua@nimr.or.tz1National Institute for Medical Research, Amani Research Centre, P. O. Box 81,
Muheza, Tanga, Tanzania
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parasitic infections [3]. Entomological field studies in
the programme areas have moreover documented a decline
in survival of female Anopheles gambiae that feed on
humans shortly after mass treatment with ivermectin [6–8].
Laboratory studies have confirmed this effect of ivermectin
on adult anopheline vector survival, and have also dem-
onstrated a reduced fecundity of these vectors following
a blood meal from ivermectin treated humans or cattle
[9, 10]. Due to this effect on important malaria vectors
in sub-Saharan Africa, ivermectin has been considered
as a potential tool for future malaria control [11, 12].
Other studies have demonstrated that non-target organ-
isms in terrestrial environments can be affected by faecal
excreta from ivermectin-treated animals, while in aquatic
environments they can be affected both directly from ex-
creta dropped in water or indirectly through runoff of iver-
mectin contaminants [13, 14]. Extensive literature on the
effect of ivermectin on non-target organisms living in ter-
restrial and aquatic environments has been summarized
previously [5]. Ivermectin has low water solubility and par-
titions rapidly in aquatic environments from the water
phase to sediment particles [15–17]. Its low water solubility
and rapid adsorption to sediments suggest that ivermectin
may pose a variable risk of exposure to aquatic organisms
living or feeding in different strata of the water body.
In sub-Saharan Africa, An. gambiae is the most import-
ant vector of malaria, and this species, as well as Culex
quinquefasciatus, are important vectors of lymphatic filar-
iasis. It is possible that the widespread use of MDA with
ivermectin could have affected transmission of these infec-
tions through an effect on the mosquito vector larvae, and
perhaps even could have contributed to the marked
change in composition of the vector mosquitoes observed
in recent years in north eastern Tanzania [18, 19]. In their
aquatic habitat anopheline and culicine larvae feed prefer-
entially in different strata of water but both come to the
surface for breathing. While anopheline larvae are mainly
surface feeders, culicine larvae feed in the sediment at the
bottom of water strata [20]. This feeding behavior may
most likely lead to differential ivermectin exposure-risks
between the two mosquito species if they reside in iver-
mectin contaminated habitats. Studies have shown that
different species of mosquito larvae are susceptible to low
concentrations of ivermectin in laboratory settings as well
as in natural mosquito breeding habitats [21, 22]. On this
background, the present study assessed and compared the
survival of An. gambiae and Cx. quinquefasciatus mos-
quito larvae when exposed to low concentrations of iver-
mectin under laboratory conditions.
Methods
Mosquito larvae
Larvae of An. gambiae sensu stricto (a colony originat-
ing from Kisumu, Kenya) and Culex quinquefasciatus (a
colony originating from Arusha, Tanzania) mosquitoes
were used for the laboratory bioassays. Both colonies
had been maintained for several generations at the in-
sectary of the National Institute for Medical Research,
Amani Research Centre, Tanga, Tanzania, and were pre-
viously also used in a study on the effect of human iver-
mectin treatment on blood feeding adult mosquitoes
[10]. They were maintained using recommended stand-
ard mosquito rearing techniques [23]. Larvae of An.
gambiae and Cx. quinquefasciatus were fed with Nutra-
fin® fish food (Hagen, Taiwan) and Whiskas® cat food
(Mars Africa, South Africa), respectively before and dur-
ing bioassays. Although both foods initially float on the
surface of the water, the cat food sinks to the bottom
relatively quickly compared to the fish food.
Preparation of ivermectin solutions
An ivermectin stock solution was first prepared by dis-
solving 200 mg powdered ivermectin (Sigma-Aldrich,
St. Louis, USA) in 20 ml dimethyl sulphoxide (DMSO)
(Hybri-Max®, Sigma-Aldrich, St. Louis, USA). The re-
sultant 1.0 % (10 mg/ml) stock solution was kept frozen
in 2 ml aliquots until use. On the experimental day,
one aliquot of stock solution was thawed and serially
diluted in distilled water as previously recommended
[24]. In brief, a ten-fold dilution series was prepared by
first transferring 2 ml of stock solution to 18 ml of dis-
tilled water to make a 0.1 % concentration, and by sub-
sequently repeating this procedure by transferring 2 ml
of the latest solution to 18 ml of distilled water to make
0.01, 0.001, 0.0001 and 0.00001 % concentrations of
ivermectin. Control solutions (with no ivermectin)
comprised of 2 ml DMSO in 18 ml distilled water.
Larval bioassays
Bioassays with An. gambiae and Cx. quinquefasciatus
larvae were run simultaneously (in parallel). For each
species twelve replicates were performed, with four rep-
licates starting on three separate dates. In each experi-
ment, 6 test cups with mosquito larvae were exposed to
six different concentrations of ivermectin (including the
negative control). At the beginning of experiments, 25
third instar larvae were transferred from the larvae rear-
ing pans to the labeled disposable plastic test cups with
100 ml of filtered non-chlorinated tap water by use of
disposable Pasteur pipettes. By using a pipette with dis-
posable tips, and starting with the lowest concentration,
1 ml of each of the six concentrations of ivermectin so-
lutions were then added to the experimental cups (with
mosquito larvae) thus giving final concentrations of 0.0,
0.001, 0.01, 0.1, 1.0 and 10.0 parts per million (ppm;
equivalent to mg/liter), respectively. The test cups were
held at 28 °C and photoperiods of 12 h light followed by
12 h darkness. Test larvae were provided with larval
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food at onset of each experiment. Larval mortality was
recorded at 24 and 48 h after the addition of ivermectin
solutions.
Data analysis
Data were entered in Excel and subsequently analyzed
in IBM SPSS Statistics (version 22). Survival of An.
gambiae and Cx. quinquefasciatus was compared using
Student’s t-test and P-values < 0.05 were considered sta-
tistically significant.
Ethics
The study received ethical approval from the Medical
Research Coordinating Committee of the National
Institute for Medical Research, Tanzania (Ref: NIMR/
HQ/R.8a/Vol. IX/1554).
Results
Twelve replicates, each testing 6 concentrations of iver-
mectin (including the negative control) each with 25 lar-
vae were conducted in parallel for a total of 1800 larvae
of both An. gambiae and Cx. quinquefasciatus. The
mean numbers (and range) of the two species surviving
at the different ivermectin concentrations at 24 and 48 h
post exposure is shown in Table 1.
Survival was high in the control groups (0.0 ppm iver-
mectin concentration), being 100 % and 99.6 % for An.
gambiae, and 100 % and 96.4 % for Cx. quinquefasciatus,
at 24 and 48 h, respectively. In both species, larval sur-
vival declined markedly with increased ivermectin con-
centration (Fig. 1). For An. gambiae, the mean survival
in 0.001, 0.01, and 0.1 ppm ivermectin at 24 h was
99.6 % (P = 0.3), 99.2 % (P = 0.07), and 61.6 % (P < 0.001),
and at 48 h was 95.2 % (P = 0.004), 81.1 % (P < 0.001),
and 3.2 % (P < 0.001) respectively, when compared to the
control group. No An. gambiae survived for 24 h in 1.0
and 10.0 ppm ivermectin. For Cx. quinquefasciatus, the
mean survival in 0.001 and 0.1 ppm of ivermectin at
24 h was 89.2 % (P = 0.001) and 47.2 % (P = 0.001) and
at 48 h it was 80.1 % (P = 0.001) and 18.7 % (P < 0.001),
respectively, when compared to the control group. No
Cx. quinquefasciatus larvae that survived for 24 h in 0.1,
1.0 or 10.0 ppm ivermectin.
Comparison between the species revealed that Cx.
quinquefasciatus larvae were more susceptible to iver-
mectin than those of An. gambiae (Table 1). At 24 h,
mean survival in An. gambiae was significantly higher
than in Cx. quinquefasciatus at ivermectin concentration
of 0.001 (P = 0.002) and 0.01 (P < 0.001) ppm. While
ivermectin concentration of 0.1 ppm at 24 h caused
100 % mortality in Cx. quinquefasciatus, the same con-
centration caused only 38.4 % mortality in An. gambiae.
At 48 h, the same pattern was seen, although mortality
was higher in both groups.
Discussion
Ivermectin is generally considered one of the most bene-
ficial biopharmaceutical drugs for use on a large scale in
veterinary and human medicine [1]. Due to its thera-
peutic effectiveness and broad spectrum of activity in
controlling many tropical parasitic diseases, it has been
argued that the scope and use of this drug may possibly
expand in the near future [25]. However, the broad
spectrum of activity has also raised concerns with re-
spect to its impact on non-target organisms in terrestrial
and aquatic environments [5]. Of particular importance
in mosquito larvae ecology, the bioavailability of iver-
mectin in aquatic environments is not homogeneous
due to its low water solubility and association with sedi-
ments. This study assessed the sensitivity of insectary
reared An. gambiae and Cx. quinquefasciatus mosquito
larvae (known to feed in different levels of the water
strata) to low concentrations of ivermectin under labora-
tory conditions.
Ivermectin concentrations in soil, groundwater, surface
water and animal dung have previously been docu-
mented, and have been shown to vary with soil type and
route and frequency of application to domestic animals
[26]. Non-target organisms have shown variable sensitiv-
ity to ivermectin, with the cladoceran Daphnia magna
Table 1 Survival of An. gambiae and Cx. quinquefasciatus larvae at different ivermectin concentrations and exposure times
Ivermectin
concentrationb
Mean no. ± SD (range) surviving at 24 hoursa Mean no. ± SD (range) surviving at 48 hoursa
An. gambiae Cx. quinquefasciatus p-value* An. gambiae Cx. quinquefasciatus p-value*
0.0 25.0 ± 0.0 (25–25) 25.0 ± 0.0 (25–25) NS 24.9 ± 0.3 (24–25) 24.1 ± 1.3 (21–25) NS
0.001 24.9 ± 0.3 (24–25) 22.3 ± 2.5 (17–25) 0.002 23.7 ± 1.3 (21–25) 19.3 ± 4.4 (12–25) 0.003
0.01 24.8 ± 0.5 (24–25) 11.8 ± 5.3 (4–22) <0.001 20.2 ± 2.5 (15–23) 4.5 ± 3.9 (0–12) <0.001
0.1 15.4 ± 6.3 (3–23) 0.0 (0–0) - 0.08 ± 0.3 (0–1) 0.0 (0–0) -
1.0 0.0 (0–0) 0.0 (0–0) - 0.0 (0–0) 0.0 (0–0) -
10.0 0.0 (0–0) 0.0 (0–0) - 0.0 (0–0) 0.0 (0–0) -
aTwelve replicates each with 25 larvae
bIn parts per million
*t-test
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being particularly sensitive with 50 % mortality after
48 h of exposure to a concentration of 0.0000057 ppm
[27]. Relatively higher ivermectin concentrations of 0.18,
0.0075, 0.78 and 4.8 ppm were found to cause 50 % mor-
tality in non-target Amphipoda, Polychaeta, Gastropoda
and Actinopterygii, respectively [28–31]. A number of
studies have indicated that photo-degradation on water
surface and rapid adsorption of ivermectin to sediments
play key roles in determining the bioavailability and en-
vironmental fate of ivermectin [32, 33]. Other studies
have indicated that benthic microcrustaceans and nema-
todes generally are more sensitive to ivermectin than
non-benthic organisms [27, 34], and this has been ar-
gued to be due to strong binding of ivermectin to soil
particles thus rendering sediment-dwelling and benthic
organisms particularly exposed [35].
In the current study, the survival of both An. gambiae
and Cx. quinquefasciatus larvae declined markedly with
increase in ivermectin concentration at both 24 and
48 hours. The study thus confirmed previous observa-
tions indicating that ivermectin at low concentrations
impairs the survival of larvae of Cx. quinquefasciatus
[21, 22, 36], and that an ivermectin-related compound
‘spinosad’ (also a macrocyclic lactone) can be effective in
controlling both anopheline and culicine mosquito lar-
vae [37–39]. The current study moreover revealed that
Cx. quinquefasciatus larvae were more susceptible to
ivermectin than those of An. gambiae at both exposure
times. For example, after 24 hours of exposure, an iver-
mectin concentration of 0.1 ppm caused 100 % larval
mortality in Cx. quinquefasciatus but only 38.4 % mor-
tality in An. gambiae. Our findings thus corroborate
with those of Romi et al. [38] who showed that the
bioinsecticide spinosad impacted more marked activity
against larvae of Culex and Aedes than against those of
Anophelines.
Inversely, previous experiments with adult mosquitoes
of the same two species showed that blood meals taken
from ivermectin treated humans significantly reduced
survival of An. gambiae but had no effect on Cx. quin-
quefasciatus [10]. The reason for this reduced sensitivity
of adult Cx. quinquefasciatus to ivermectin in blood
meals is a subject for further research. However, the dif-
ference in susceptibility to ivermectin in aqueous envi-
ronments between larvae of the same two species of
mosquitoes may in part be associated with the physical
properties of ivermectin of low water solubility and rapid
adsorption to sediments [15, 16], in combination with
the sedimentation of the larval feeds. Thus, it is likely
that the larval food particles that sink increase ivermec-
tin bioavailability at the bottom while depleting the same
at the water surface. Being surface feeders, An. gambiae
larvae would be less exposed to ivermectin than the bot-
tom feeding Cx. quinquefasciatus larvae. Although it
cannot be excluded that Cx. quinquefasciatus larvae are
inherently more susceptible to ivermectin than An. gam-
biae larvae, it appears likely that the former species is
considerably more exposed to the drug due to its bottom
feeding habit, and that this may be a major cause for the
higher mortality observed for this species. More studies
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should be carried out in controlled environments to
confirm to what extent feeding and dwelling characteris-
tics determine the survival of mosquito larvae in iver-
mectin contaminated habitats. Field studies should also
be undertaken to examine to what extends breeding sites
are contaminated in areas with ivermectin mass drug ad-
ministration and its effect on mosquito larvae.
Conclusions
Low concentrations of ivermectin in the aquatic envir-
onment reduced the survival of larvae of An. gambiae
and Cx. quinquefasciatus, with the effect being more
marked in the latter than the former species. As iver-
mectin has low water solubility and adsorb rapidly to
sediments in aquatic environment, this difference in
mosquito survivorship may be due to the bottom feeding
Cx. quinquefasciatus larvae being more heavily exposed
to ivermectin than the surface feeding An. gambiae lar-
vae. The observed effects on the larvae suggest that iver-
mectin finding its way to the environment after
administration to humans or animals could indirectly
affect the vector populations, with different effect on
different species, and thereby the transmission of
mosquito-borne infections.
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